@entity2682 in antipsychotic-induced XXXX : results of 1-year follow-up.

@entity1 @entity162 @entity2682 @entity910 @entity161
BACKGROUND: In a previous study, improvement of antipsychotic-induced blefarospasm and involuntary oral-mandibulo movements were observed with the use of the anticonvulsant drug @entity2682 among affectively ill @entity1 who had been exposed to maintenance neuroleptics. The results reported in the present paper represent the sequel to the previous study. METHODS: The purported efficacy of @entity2682 in the treatment of @entity910 has been assessed in an open design 1-year follow-up study, in which 30 schizoaffective, @entity162 and @entity161 @entity1 from seven Italian centres were evaluated by means of AIMS. The results showed a statistically significant time-related decrease in AIMS scores. The mean percentage of improvement at AIMS was 47.5+/-18.2%. An improvement of more than 35% after 1 year in 76% of the subjects who completed the trial (n=25) and in 63.3% of the entire sample admitted to the study was revealed. LIMITATION: Open trial. CONCLUSION: The introduction of new antipsychotic drugs has probably already limited the problems related to @entity910 . However, this type of side-effect is also observed during the course of treatment with atypical neuroleptics albeit with a lesser frequency. The fact that @entity2682 treatment may have further improved clinical conditions of @entity1 in whom therapeutic protocols had already been modified, appears to suggest exertion of a possible synergic action by the new neuroleptics on @entity910 .
